Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 15/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 15/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 15/20 | 0.74 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28538595 | 0.92 | CHRM2 (0.74) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL28702389 | 0.82 | CHRM2 (0.60) | CHRM2CHRM1CHRM3TSHRRXFP1 | |
| SCHEMBL28644233 | 0.79 | CHRM3 (0.87) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL28541415 | 0.79 | CHRM2 (0.78) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL28527169 | 0.79 | CHRM2 (0.78) | CHRM2CHRM1CHRM3TSHRRXFP1 | |
| SCHEMBL28532845 | 0.77 | CHRM3 (0.71) | CHRM2CHRM1CHRM3 | |
| SCHEMBL28547261 | 0.77 | CHRM2 (0.75) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL28537600 | 0.77 | CHRM3 (0.75) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL28537710 | 0.76 | CHRM2 (0.60) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| SCHEMBL12615363 | 0.74 | ALDH1A1 (0.53) | CHRM3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107080747-B | Glucosylceramide synthase inhibitors | 建新公司 | 2021-02-26 | — | — | CN | disclosed |